Omega Funds

Founded 2004
Founders Otello Stampacchia

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 98
Average round size
info
The average size of a deal this fund participated in
$56M
Portfolio companies 81
Rounds per year 5.76
Lead investments 18
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.22
Exits 45
Key employees 3
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Pharmaceutical
  • Medical
Summary

The company was established in North America in United States. The leading representative office of defined VC is situated in the Boston.

Deals in the range of 10 - 50 millions dollars are the general things for fund. The increased amount of exits for fund were in 2019. The fund is generally included in 2-6 deals every year. Comparing to the other companies, this Omega Funds performs on 7 percentage points more the average number of lead investments. Speaking about the real fund results, this VC is 0 percentage points less often commits exit comparing to other organizations. The high activity for fund was in 2017.

Besides them, we counted 3 critical employees of this fund in our database.

Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Intarcia Therapeutics, Gossamer Bio, Beam Therapeutics. The fund has no exact preference in some founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the most popular fund investment industries, there are Biotechnology, Medical.

The standard case for the fund is to invest in rounds with 6-7 partakers. Despite the Omega Funds, startups are often financed by Polaris Partners, Flagship Pioneering, New Enterprise Associates. The meaningful sponsors for the fund in investment in the same round are New Enterprise Associates, Abingworth, The Baupost Group. In the next rounds fund is usually obtained by Polaris Partners, Atlas Venture, The Baupost Group.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Omega Funds:
Typical Co-investors
Omega Funds is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Omega Funds:

Funds with similar focus

Funds from United States, Boston
Funds with similar focus located in United States, Boston:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
NEWAY Capital United States, Washington
Simpel India, Mumbai
Brio Capital Management United States, New York
Pentech Ventures United Kingdom, City of Edinburgh
TrustCapital India, Mumbai
MAN Truck & Bus Germany, Munich
SunTrust Bank United States, Atlanta
Aesop Capital United States, San Francisco
3W Partners United States, Saint Louis
Shenshang Xingye Fund -
SAINT-CARE HOLDINGS Japan, Tokyo
Yanlingxian Qianqian Shangmao China, Henan
JNS HOLDINGS Japan, Tokyo
Shenzhen Qianhai Huaye Yuan Touzi China, Shenzhen
Platform Investment Partners South Africa, Johannesburg
Ufi Ventures United Kingdom, London
TCG Crossover United States, Palo Alto
Lantern Community Primary School - Crunchbase School Profile & Alumni United Kingdom, Ely
SunTrust Bank United States, Atlanta
NEWAY Capital -
Simpel India, Mumbai
Mintian Capital -
Assets New Ventures -

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

Artios Pharma

Biopharma
Biotechnology
Medical Device
1
$150M27 Jul 2021 United Kingdom, Cambridge

Synthekine

Biotechnology
Therapeutics
1
$107M10 Jun 2021 United States, " United States"}

Adagio Therapeutics

Biotechnology
Pharmaceutical
Therapeutics
1
$336M19 Apr 2021 United States, " United States"}

Biotechnology
Health Care
Information Technology
Pharmaceutical
Travel
1
$100M13 Apr 2021 United States, New York

Scorpion Therapeutics

Biotechnology
Health Care
Life Science
1
$162M07 Jan 2021 United States, Boston

Ikena Oncology

Biotechnology
Health Care
Therapeutics
1
$120M05 Jan 2021 United States, Boston

Syros Pharmaceuticals

Biotechnology
Genetics
Life Science
Pharmaceutical
1
$90M07 Dec 2020 United States, " United States"}

Adagio Therapeutics

Biotechnology
Pharmaceutical
Therapeutics
1
$80M10 Nov 2020 United States, " United States"}

Scorpion Therapeutics

Biotechnology
Health Care
Life Science
1
$108M26 Oct 2020 United States, Boston
News
Anjarium Biosciences Raises $61M in Series A Financing

– Anjarium Biosciences AG is a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies.
– Series A funding closed at $61m.
– The round was co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company).
– The new investment will be used to advance the company’s pipeline programs towards clinical development.

Anjarium Biosciences Raises $61M in Series A Financing

– Anjarium Biosciences AG is a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies.
– Series A funding closed at $61m.
– The round was co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company).
– The new investment will be used to advance the company’s pipeline programs towards clinical development.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Omega Funds?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: